Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue: 2017-2024

Historic Non-Current Deffered Revenue for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $4.7 million.

  • Crinetics Pharmaceuticals' Non-Current Deffered Revenue fell 20.89% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 20.89%. This contributed to the annual value of $4.7 million for FY2024, which is 0.97% down from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Non-Current Deffered Revenue is $4.7 million, which was down 0.97% from $4.8 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $6.1 million for FY2022, and its period low was $2,000 during FY2021.
  • In the last 3 years, Crinetics Pharmaceuticals' Non-Current Deffered Revenue had a median value of $4.8 million in 2023 and averaged $5.2 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Non-Current Deffered Revenue tumbled by 91.30% in 2021 and then skyrocketed by 304,950.00% in 2022.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Non-Current Deffered Revenue stood at $23,000 in 2020, then plummeted by 91.30% to $2,000 in 2021, then soared by 304,950.00% to $6.1 million in 2022, then fell by 22.14% to $4.8 million in 2023, then decreased by 0.97% to $4.7 million in 2024.